Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
February 8, 2022
RegMed Investors’ (RMi) closing bell: we had a pitcher in this session, the pitcher's nick-name - Algorithm
February 7, 2022
RegMed Investors’ (RMi) closing bell: another bounce, dips got bought yet, the sector could end-up with overbought and volatile bottoms again
February 4, 2022
RegMed Investors’ (RMi) closing bell: Volatility fell, volume was lower in a positive cell and gene therapy sector close
February 3, 2022
RegMed Investors’ (RMi) closing bell: another wild run
February 2, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector got hammered as predicted, when is it wrong to be so right and often?
February 1, 2022
RegMed Investors’ (RMi) closing bell: are you making a return on investments (ROI) or waiting for the down slide
January 31, 2022
RegMed Investors’ (RMi) closing bell: I said, take the highs and sell them, there’s always a question of how long the upsides will last
January 28, 2022
RegMed Investors’ (RMi) closing bell: a daily reversal with a big positive sector close after a frustrating week for cell and gene therapy investors
January 27, 2022
RegMed Investors’ (RMi) closing bell: the costs of the roller-coaster sector rides
January 26, 2022
RegMed Investors’ (RMi) closing bell: I loved the smell of appreciation in the morning until the algorithms napalmed the cell and gene therapy sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
Stemline Therapeutics (STML) -- STML opened on 1/2/18 at $15.65 and closed on 3/31 at $15.85 and March at $16.75 with a high (3/6/18) at 17.20 ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors